

An Intensive Workshop on Antiretroviral Strategies: New Drugs, Antiretroviral Failure, and Resistance Testing

New York, NY

Thursday, March 13, 2008

8:30 AM – 12:00 N

Weill Greenberg Center

1305 York Avenue

(York Avenue and 70th Street)

New York, NY 10021-5663

This workshop is offered in collaboration with the NY-NJ AIDS Education and Training Center.

Workshop Faculty

Roy M. Gulick, MD, MPH
Professor of Medicine
Director of Cornell HIV Clinical Trials Unit
Division of International Medicine and
Infectious Diseases
Weill Cornell Medical College

David M. Margolis, MD
Professor of Medicine, Microbiology & Immunology,
and Epidemiology
School of Public Health
University of North Carolina at Chapel Hill

Who Should Attend

Experienced HIV clinical decision makers (MDs, DOs, NPs, PAs) caring for HIV patients with a working knowledge of HIV disease management.

Overview and Assessment of Needs

Expert faculty will speak in a small-group interactive setting on timely and clinically relevant issues in HIV disease management such as:

- Management strategies for antiretroviral failure
- Role of resistance testing to determine treatment options for patients with multiple drug resistance mutations
- Role of new drugs in failure regimens

Rapid advances in these areas require the ongoing attention of practitioners involved in HIV medicine. The course will address the implications of this information on strategies for antiretroviral therapy.

Learning Objectives

Upon completion of the workshop, participants will be able to:

- Design appropriate treatment strategies for patients experiencing antiretroviral failure that consider current data on new drugs, new classes, and new assays
- Identify the elements of an effective salvage regimen
- Compare and contrast the benefits and limitations of genotypes and phenotypes
- Explain the effective use of tropism assays and how they may fit into the management of HIV-infected patients
- Examine the risk and activity and the resistance profiles of new and emerging antiretroviral drugs

CME Accreditation Statement

The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

Credit Designation Statement

The International AIDS Society–USA designates this educational activity for a maximum of 3.25 *AMA PRA Category 1 Credits*.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

Registration

The registration fee is \$30. Fax or mail your complete registration form (below) with payment. Registration closes March 6, 2008. Registrations will be accepted on a first-come, first-served basis. Attendance is limited to 40 participants. Forms should be mailed or faxed to:

International AIDS Society-USA
425 California Street, Suite 1450
San Francisco, CA 94104-2120
Tel: 415-544-9400
Fax: 415-544-9401

Conflicts of Interest

Information regarding conflicts of interest is obtained from all parties with control over the activity content (ie, Board of Directors, workshop development committee, workshop leaders, and IAS-USA staff), and any conflicts of interest of those parties are resolved prior to the activity being delivered.

Funding

This activity is made possible by educational grants from several commercial companies that are committed to supporting independent CME in the field of HIV/AIDS. Major grant support has been provided by: Bristol-Myers Squibb, Pfizer Global Pharmaceuticals, and Merck & Co., Inc.

+ + +

**An Intensive Workshop on Antiretroviral Strategies:
 New Drugs, Antiretroviral Failure, and Resistance Testing**

Workshop registrants are encouraged to submit their own difficult clinical cases for potential inclusion in the workshop discussion, using the form below. Please complete the form below, include resistance test results, and submit via email (tnichol@iasusa.org) or fax (415-544-9401).

Date of patient review: _____

Resistance test: genotype, phenotype, pheno GT Date of Test: _____

ARV treatment when tested: _____

Adherence assessment: Score: _____ Excellent, Good, Fair, Poor Date: _____

Most recent viral load: _____ Date: _____ Most recent CD4+: _____ Date: _____

Viral load before ARV: _____ Date: _____ Highest viral load recorded: _____ Date: _____

Lowest CD4+: _____ Date: _____ ARV history: high confidence, low confidence

Past Resistance Tests: 1) _____ 2) _____ 3) _____

Past Detected Mutations: NRTI: _____

NNRTI: _____ PI: _____

ARV past history	Date started...ended	Reason discontinued
Regimen 1: _____	_____	_____
Regimen 2: _____	_____	_____
Regimen 3: _____	_____	_____
Regimen 4: _____	_____	_____
Regimen 5: _____	_____	_____
Regimen 6: _____	_____	_____
Regimen 7: _____	_____	_____
Regimen 8: _____	_____	_____

Exposure to: (circle all that apply)

NRTIs: abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, zidovudine

NNRTIs: delavirdine, efavirenz, nevirapine

PIs: amprenavir, atazanavir, indinavir, fosamprenavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir

Fixed-dose combinations: abacavir/lamivudine, emtricitabine/tenofovir, lamivudine/zidovudine, lamivudine/zidovudine/abacavir

Fusion Inhibitor: enfuvirtide

Investigational/Expanded access drugs: _____

 Confounders (circle): neuropathy, pancreatitis, dyslipidemia, elevated lft's, lipoatrophy, CNS symptoms, hyperlactatemia, lactate acidosis, depression, anemia, neutropenia, TB, HBV, HCV,
 Other: _____

Allergy history: _____

ARV drug intolerance: _____

Patient refuses: _____

Recommendation: _____

Next clinic visit: _____ Next retro visit: _____